New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients
A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the…